metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA) 3
mHCC - 1st line (L1) 10
mHCC - 2nd line (L2) 2
lung cancer : non small cell (NSCLC) 5

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone

versus all
vs non active control
vs placebo

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open